Valuation: Omeros Corporation

Market Cap 1.18B 1.06B 977M 889M 1.67B 112B 1.69B 11.72B 4.61B 58.65B 4.44B 4.35B 187B P/E 2026 *
18x
P/E 2027 * 15.5x
Enterprise Value 1.18B 1.06B 977M 889M 1.67B 112B 1.69B 11.72B 4.61B 58.65B 4.44B 4.35B 187B EV / Sales 2026 *
9.28x
EV / Sales 2027 * 5.35x
Free-Float
95.92%
Yield 2026 *
-
Yield 2027 * -
1 day+0.93%
1 week-16.71%
Current month-14.13%
1 month-8.51%
3 months+68.73%
6 months+21.65%
Current year-4.80%
1 week 15.84
Extreme 15.845
19.27
1 month 15.84
Extreme 15.845
21.24
Current year 6.7
Extreme 6.7023
21.24
1 year 6.24
Extreme 6.24
21.24
3 years 1.05
Extreme 1.05
21.24
5 years 0.92
Extreme 0.92
21.24
10 years 0.92
Extreme 0.92
27.09
Manager TitleAgeSince
Chief Executive Officer 67 1994-06-15
Director of Finance/CFO 62 2024-06-29
Chief Tech/Sci/R&D Officer 70 2019-10-31
Director TitleAgeSince
Chairman 67 1994-06-15
Director/Board Member 86 1994-12-31
Director/Board Member 72 1994-12-31
Date Insider Type Main position Quantity % Market Cap. Importance
9/23/26 Exercice

Chief Financial Officer

30,000 0.0414%
8/31/26 Exercice

General Counsel

75,000 0.1036%
8/27/26 Exercice

Director

30,000 0.0415%
Change 5-day change 1-year change 3-year change Capi.($)
+0.93%-16.71%+101.73%+1,197.62% 1.17B
+1.52%-7.19%+51.66%+69.99% 65B
+1.52%+6.83%+10.77%+79.30% 51.2B
+0.30%-0.46%+2.53%+61.89% 51.19B
-0.38%+1.40%+29.98%+42.37% 43.93B
+0.30%+5.64%+16.99%+133.30% 41.96B
+2.35%-6.08%+236.69%+528.10% 38.14B
+2.16%+9.87%+18.92%+59.70% 33.24B
+6.02%+0.10%+42.66%+11.28% 25.2B
+1.60%+2.21%+21.34%+28.00% 22.5B
Average +1.67%-1.71%+53.33%+221.15% 37.35B
Weighted average by Cap. +1.47%-0.21%+46.58%+116.93%

Financials

2026 *2027 *
Net sales 128M 114M 105M 95.73M 180M 12.09B 183M 1.26B 497M 6.32B 478M 468M 20.2B 221M 197M 183M 166M 312M 20.98B 317M 2.19B 862M 10.97B 830M 813M 35.06B
Net income 64.97M 57.91M 53.65M 48.78M 91.53M 6.16B 93.03M 643M 253M 3.22B 244M 239M 10.29B 84.8M 75.59M 70.02M 63.67M 119M 8.04B 121M 840M 330M 4.2B 318M 312M 13.43B
Net Debt - -
Projected Income Statement - Annual - Omeros Corporation
Logo Omeros Corporation
Omeros Corporation is a clinical-stage biopharmaceutical company. The Company focuses on discovering, developing, and commercializing first-in-class small-molecule and protein therapeutics for both large-market and orphan indications, with a particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. Its clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program. Its commercial product, YARTEMLEA, is the approved inhibitor of the lectin pathway of complement. YARTEMLEA is used for the treatment of TA-TMA in adults and in children ages two years and older. YARTEMLEA selectively inhibits MASP-2, blocking pathway activation while preserving classical and alternative complement pathway functions.
Employees
175
Date Price Change Volume
26-10-19 US$16.35 +0.93% 1,382,868
26-10-16 US$16.20 -13.78% 3,965,862
26-10-15 US$18.79 +1.95% 931,367
26-10-14 US$18.43 -2.38% 905,106
26-10-13 US$18.88 -3.82% 994,056
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
MarketScreener Ratings - Omeros Corporation
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
16.35USD
Average target price
27.50USD
Spread / Average Target
+68.20%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Omeros Corporation
  1. Stock Market
  2. Stocks
  3. OMER Stock